Stocktoria
Aligos Therapeutics, Inc. ALGS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-16
Chart by TradingView
3/9
Piotroski F — financial health
-24.15
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $2.2M | $3.6M | $6.2M | $0 | $0 |
| Operating income | -$88.0M | -$89.2M | -$88.1M | -$97.6M | -$128.3M |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M | -$128.3M |
| Operating cash flow | -$82.5M | -$80.7M | -$79.0M | -$79.4M | -$115.7M |
| Free cash flow | — | -$80.9M | -$79.0M | -$80.3M | -$116.6M |
| Total assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M |
| Total liabilities | $35.0M | $99.1M | $59.4M | $42.8M | $50.6M |
| Shareholders' equity | $53.5M | -$29.0M | $92.1M | $103.9M | $184.7M |
| Ratios | |||||
| Operating margin | -4024.9% | -2469.0% | -1423.5% | — | — |
| Net margin | -1106.7% | -3633.6% | -1416.2% | — | — |
| FCF margin | — | -2239.6% | -1276.3% | — | — |
| Return on assets | -27.3% | -187.2% | -57.9% | -65.5% | -54.5% |
| Return on equity | -45.2% | 452.9% | -95.2% | -92.4% | -69.5% |
| Current ratio | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 |
| Revenue growth | -39.5% | -41.7% | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 100,450 | $746,344 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -24.15 (distress)
- Working capital / assets 0.696
- Retained earnings / assets -7.254
- EBIT / assets -0.994
- Equity / liabilities 1.53
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001799448 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.